ABSTRACT
Objective To analyze the clinical efficacy of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma. Methods 100 patients with acute attack of asthma treated from March 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group received terbutaline sulfate inhalation, and the experimental group received ipratropium bromide combined with terbutaline sulfate inhalation treatment. The patients in the experimental group and the control group were treated for 7 days continuously. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group (94.0%) was significantly higher than that in the control group (72.0%),the difference was statistically significant(P<0.05). The improvement time of dyspnea, rale and cough in control group was significantly longer than that in the experimental group, the difference was statistically significant(P<0.05). Conclusion Ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma has better clinical efficacy and shorter clinical symptoms.
ABSTRACT
Objective To analyze the clinical efficacy of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma. Methods 100 patients with acute attack of asthma treated from March 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group received terbutaline sulfate inhalation, and the experimental group received ipratropium bromide combined with terbutaline sulfate inhalation treatment. The patients in the experimental group and the control group were treated for 7 days continuously. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group (94.0%) was significantly higher than that in the control group (72.0%),the difference was statistically significant(P<0.05). The improvement time of dyspnea, rale and cough in control group was significantly longer than that in the experimental group, the difference was statistically significant(P<0.05). Conclusion Ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma has better clinical efficacy and shorter clinical symptoms.
ABSTRACT
OBJECTIVE:To compare therapeutic efficacy and safety of budesonide or beclometasone combined with terbutanline in the treatment of acute attack of mild and moderate asthma in children.METHODS:A total of 110 children with mild and moderate asthma were randomly divided into group A (55 cases) and group B (55 cases).Based on routine treatment,group A was given Terbutaline sulphate solution for nebulization 1 mL,nebulization inhalation,twice a day+Budesonide suspension for inhalation 2 mL,nebulization inhalation,twice a day.Group B was given Terbutaline sulphate solution for nebulization (same usage and dosage as group A)+Beclomethasone dipropionate suspension for inhalation 2 mL,nebulization inhalation,twice a day.Treatment courses of 2 groups lasted for 7 d.Clinical efficacies,symptoms and signs disappearance time,hospitalization time,asthma relief rate as well as symptoms and signs scores,peak value expiration velocity of flow (PEF),the occurrence of ADR were observed in 2 groups.RESULTS:There was no statistical significance in total response rate,symptoms and signs disappearance time,hospitalization time,asthma relief rate or the incidence of ADR between 2 groups (P＞0.05).After treatment,symptoms and signs scores of 2 groups were significantly lower than before,while the PEF were significantly higher than before,with statistical significance (P＜0.05),but there was no statistical significance between 2 groups (P＞0.05).CONCLUSIONS:Based on routine treatment,budesonide or beclometasone combined with terbutaline sulphate can be used for acute attack of mild and moderate asthma in children.They are similar to each other in therapeutic efficacy and safety.
ABSTRACT
Objective To assess the value of serum amyloid A (SAA) in patients with acute asthma attack. Methods Sixty-four asthmatic patients in acute phase and 20 healthy individuals were included. The asthmatic patients were divided into bacterial infection-induced group and non-bacterial infection-induced group. Lung function test and chest X-rays test were conducted And inflammatory cell counts , serum SAA and CRP levels were measured. SAA were compared among subgroups of asthmatic patients and healthy controls and the diagnostic value of SAA to distinguish bacterial infection-induced asthma was estimated. Results SAA of both asthma subgroups were significantly higher when compared with the healthy individuals, and it was higher in bacterial infection-induced group than that in non-bacterial infection-induced group. In terms of ROC curve , AUC was 0.966 for SAA to distinguish merging bacterium infection, and the cut-off value was 36.67mg/L with sensitivity of 92.3% and specificity of 88.2%. Conclusions SAA increases in patients during acute asthma attack, and particularlymore obviously in bacterial infection-induced patients. It may be used as a reliable biomarker to distinguish merging bacterium infection during acute asthma attack.